Intra-tumoral administration of L19-TNF-α, a combination anti-cancer therapy, showed significant anti-melanoma activity in a phase II clinical trial in patients with advanced stage metastatic melanoma [39]. The gene discussed is TNF; the disease is metastatic melanoma.